These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31577867)

  • 1. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
    Newcomer JW; Eriksson H; Zhang P; Meehan SR; Weiss C
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31577867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Metabolic Parameters and Body Weight in Patients With Prediabetes Treated With Adjunctive Brexpiprazole for Major Depressive Disorder: Pooled Analysis of Short- and Long-Term Clinical Studies.
    Newcomer JW; Meehan SR; Chen D; Brubaker M; Weiss C
    J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37656180
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
    Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies.
    Newcomer JW; Eriksson H; Zhang P; Weiller E; Weiss C
    Curr Med Res Opin; 2018 Dec; 34(12):2197-2205. PubMed ID: 29985680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
    McIntyre RS; Weiller E; Zhang P; Weiss C
    J Affect Disord; 2016 Sep; 201():116-23. PubMed ID: 27208498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
    Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
    Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
    Hobart M; Zhang P; Weiss C; Meehan SR; Eriksson H
    Int J Neuropsychopharmacol; 2019 Mar; 22(3):173-179. PubMed ID: 30508090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies.
    Thase ME; Zhang P; Weiss C; Meehan SR; Hobart M
    Expert Opin Pharmacother; 2019 Oct; 20(15):1907-1916. PubMed ID: 31290344
    [No Abstract]   [Full Text] [Related]  

  • 12. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.
    Hobart M; Zhang P; Skuban A; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychopharmacol; 2019; 39(3):203-209. PubMed ID: 30946704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Adjunctive Brexpiprazole on Individual Depressive Symptoms and Functioning in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of Three Placebo-Controlled Studies.
    McIntyre RS; Bubolic S; Zhang Z; MacKenzie EM; Therrien F; Miguelez M; Boucher M
    J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):133-140. PubMed ID: 38421922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
    Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder.
    Clayton AH; Ivkovic J; Chen D; George V; Hobart M
    J Clin Psychopharmacol; 2020; 40(6):560-567. PubMed ID: 33136923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
    Nelson JC; Weiller E; Zhang P; Weiss C; Hobart M
    J Affect Disord; 2018 Feb; 227():103-108. PubMed ID: 29055257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
    Lepola U; Hefting N; Zhang D; Hobart M
    Int J Geriatr Psychiatry; 2018 Oct; 33(10):1403-1410. PubMed ID: 30039634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
    Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
    Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.